One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...

What is Short Hairpin RNA? RNA serves a wide variety of roles within a cell, carrying out catalytic, regulatory, structural and genetic transferal functions. A type of artificial RNA, called short ...

The Food and Drug Administration on Friday granted the first U.S. approval of a drug that works by 'silencing' genes to halt disease, completing a 16-year research journey for Alnylam Pharmaceuticals, ...

According to SNS Insider, the global RNAi Technology Market was valued at USD 3.02 billion in 2024 and is projected to reach USD 9.03 billion by 2032, expanding at a CAGR of 14.68% over 2025–2032. RNA ...

RNA interference (RNAi) is an ancient genetic regulatory mechanism that modern-day scientists are trying to harness. Since its discovery more than 10 years ago, RNAi R&D has run the gamut from ...

A Cornucopia of siRNA- and RNAi-based Therapeutics in Development Show Promise Researchers from academia and industry will present the latest developments in the application of interference RNA (RNAi) ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

— Milestone Achievement Reflects First Investigational Candidate to Emerge Under Multi-Target Collaboration and Triggers $10 Million Payment to Dicerna — – Lilly Targeting Initiation of Phase 1 ...

- Company Expects to Initiate a Phase 1 Study in Early-Onset Alzheimer’s Disease in Early 2022, with Initial Human Data at or Around Year-End 2022 - - ALN-APP Marks the Industry’s First-Ever RNAi ...

The first sprayable insecticide made of RNA can target and kill ravenous Colorado potato beetles while sparing most ...